BioRestorative Therapies (BRTX) Operating Leases (2019 - 2024)

BioRestorative Therapies (BRTX) has reported Operating Leases for 6 consecutive years, with $42414.0 the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Operating Leases fell 78.66% year-over-year to $42414.0; the trailing twelve-month figure through Sep 2024 stood at $42414.0 (down 78.66% YoY), and the FY2023 full-year result was $162317.0, changed 0.0% from the prior year.
• Operating Leases retreated to $42414.0 in Q3 2024 per BRTX's latest filing, from $83580.0 in the prior quarter.
• Across five years, Operating Leases topped out at $497714.0 in Q1 2020 and bottomed at $42414.0 in Q3 2024.
• Historically, Operating Leases has averaged $270906.9 across 5 years, with a median of $268357.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Leases changed 0.0% in 2023, then slumped 78.66% in 2024.
• Over 5 years, Operating Leases stood at $363519.0 in 2020, then fell by 17.02% to $301645.0 in 2021, then sank by 46.19% to $162317.0 in 2022, then changed by 0.0% to $162317.0 in 2023, then tumbled by 73.87% to $42414.0 in 2024.
• According to Business Quant data, Operating Leases over the past three periods registered $42414.0, $83580.0, and $123536.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.